Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
Vorangegangene Reperfusionsstrategie verändert das Ergebnis beim frühen versus späten Beginn von Antikoagulanzien bei Patient:innen mit ischämischem Schlaganfall nicht: präspezifizierte Subanalyse der randomisierten ELAN-Studie
Stroke · 2025-08 · 56 (8) · 2000-2008
DOI: 10.1161/strokeaha.125.050646 ↗Auf einen Blick
In einer Subanalyse der ELAN-Studie änderte eine vorangegangene Reperfusionsbehandlung den Effekt eines frühen versus späten DOAC-Beginns nicht. Die Ereignisraten waren in mehreren Gruppen numerisch niedriger unter früher Therapie.
Fragestellung
Modifiziert eine vorangegangene Reperfusionsbehandlung den Effekt eines frühen versus späten DOAC-Beginns nach akutem ischämischem Schlaganfall?
Methode
Post-hoc-Analyse der multizentrischen randomisierten ELAN-Studie; eingeschlossen wurden Teilnehmende mit Angaben zur Reperfusionsbehandlung; logistische Regression mit Interaktionsterm.
Ergebnisse
Eingeschlossen waren 1973 von 2013 Patient:innen, medianes Alter 77 (71–84) Jahre, 899 (46%) Frauen. Keine Interaktion zwischen Reperfusionsstrategie und Timing des DOAC-Beginns für die Endpunkte; z. B. ohne Reperfusion 17 (3,3%) vs. 24 (4,8%; aOR 0,69; 95 %-KI 0,36–1,28).
Schlussfolgerung der Autor:innen
Eine vorangegangene Reperfusionsbehandlung verändert den Effekt eines frühen versus späten DOAC-Beginns auf klinische Ergebnisse bei Patient:innen mit Vorhofflimmern und akutem ischämischem Schlaganfall nicht.
Kernaussagen
- Keine Interaktion zwischen Reperfusion und frühem/spätem DOAC-Beginn
- 1973/2013 Patient:innen der ELAN-Studie analysiert
- Beispiel: ohne Reperfusion 3,3% vs. 4,8%
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025-08. Verfasst von Anke Wouters und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute, Belgium (A.W., J. Demeestere, R.L.). Hauptthemen laut MEDLINE: Ischemic Stroke, Anticoagulants, Atrial Fibrillation, Reperfusion. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Early initiation of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and acute ischemic stroke is beneficial and safe. Whether prior acute reperfusion therapy modifies the treatment effect of early versus late DOAC initiation is unknown. METHODS: For this post hoc analysis of the multicenter, randomized controlled ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation), all participants with data concerning reperfusion treatment were included. The primary outcome was the composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Patients were divided into 4 groups based on prior reperfusion therapy: no treatment, intravenous thrombolysis (IVT), endovascular treatment (EVT), or IVT combined with EVT. We performed logistic regression adjusted for age, hypertension, infarct location/size, pre-modified Rankin Scale, NIHSS, and hemorrhagic transformation, including the interaction term between treatment groups (early versus late DOAC) and reperfusion strategy. RESULTS: We included 1973 of 2013 (98%) patients of the ELAN trial population, with a median age of 77 (71–84) years and of whom 899 (46%) were female. Of them, 1015 (51%) underwent no prior reperfusion treatment, 519 (26%) IVT, 190 (10%) EVT, and 249 (13%) IVT+EVT. We did not identify an interaction for any of the outcome events between prior reperfusion therapy and timing of DOAC initiation. Rates were numerically lower in the early DOAC-initiated group for the following: no reperfusion therapy, 17 (3.3%) versus 24 (4.8%; adjusted odds ratio, 0.69 [95% CI, 0.36–1.28]); EVT, 1 (1.2%) versus 7 (6.4%; adjusted odds ratio, 0.25 [95% CI, 0.03–1.21]); and EVT+IVT, 3 (2.4%) versus 4 (3.3%; adjusted odds ratio, 0.76 [95% CI, 0.17–3.23]). In patients who had received IVT, the rates were 3% (n=8) in the early group versus 2% (n=5) in the late group (adjusted odds ratio, 1.52 [95% CI, 0.52–4.84]). CONCLUSIONS: Prior reperfusion therapy does not modify the effect of early versus late DOAC initiation on clinical outcomes in patients with atrial fibrillation and acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute, Belgium (A.W., J. Demeestere, R.L.).
- Department of Neurology, University Hospitals Leuven, Belgium (J. Demeestere, A.D., R.L.).
- Department of Clinical Research (J.-B.R.), University of Bern, Switzerland.
- Department of Neurology, Stroke Unit, CHC Montlégia Hospital, Liège, Belgium (P.D.).
- Department of Neurology, Algemeen Ziekenhuis Groeninge Kortrijk, Belgium (P.V.).
- Department of Neurology, Ghent University Hospital, Belgium (D.H.).
ORCID-Profile: Anke Wouters, Jelle Demeestere, Philippe Desfontaines, Peter Vanacker, Dimitri Hemelsoet, Laetitia Yperzeele, Jan Vynckier, Takeshi Yoshimoto, Kanta Tanaka, Jochen Vehoff, Caterina Kulyk, Alexander Salerno, Takenobu Kunieda, Arsany Hakim, Roman Rohner, Stefanie Abend, Martina Goeldlin, Jesse Dawson, Urs Fischer, Robin Lemmens
Zitieren
APA
Wouters, A., Demeestere, J., Rossel, J. B., Devroye, A., Desfontaines, P., Vanacker, P., Hemelsoet, D., Yperzeele, L., Rutgers, M. P., Peeters, A., Vynckier, J., Yoshimoto, T., Tanaka, K., Vehoff, J., Matsuzono, K., Kulyk, C., Sibolt, G., Slade, P., Salerno, A., …, & ELAN Investigators (2025). Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial. Stroke, 56(8), 2000-2008. https://doi.org/10.1161/strokeaha.125.050646
Vancouver
Wouters A, Demeestere J, Rossel JB, Devroye A, Desfontaines P, Vanacker P, et al. Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial. Stroke. 2025;56(8):2000-2008. doi:10.1161/strokeaha.125.050646
BibTeX
@article{Wouters2025,
author = {Wouters, Anke and Demeestere, Jelle and Rossel, Jean-Benoît and Devroye, Annemie and Desfontaines, Philippe and Vanacker, Peter and Hemelsoet, Dimitri and Yperzeele, Laetitia and Rutgers, Matthieu Pierre and Peeters, André and Vynckier, Jan and Yoshimoto, Takeshi and Tanaka, Kanta and Vehoff, Jochen and Matsuzono, Kosuke and Kulyk, Caterina and Sibolt, Gerli and Slade, Peter and Salerno, Alexander and Kunieda, Takenobu and Hakim, Arsany and Rohner, Roman and Abend, Stefanie and Goeldlin, Martina and Dawson, Jesse and Fischer, Urs and Lemmens, Robin and ELAN Investigators, ELAN Investigators},
title = {Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial},
journal = {Stroke},
year = {2025},
volume = {56},
number = {8},
pages = {2000--2008},
doi = {10.1161/strokeaha.125.050646}
}
EUVIMED